Abdominal Pain News and Research RSS Feed - Abdominal Pain News and Research

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.
Groundbreaking research findings could lead to potential new treatments for Crohn’s disease

Groundbreaking research findings could lead to potential new treatments for Crohn’s disease

A Case Western Reserve University School of Medicine-led team of international researchers has for the first time identified a fungus as a key factor in the development of Crohn's disease. [More]
Research strongly links smoking to bowel condition relapses

Research strongly links smoking to bowel condition relapses

Smoking is strongly linked to relapse of a serious bowel condition, research has confirmed. [More]
Cases of rotavirus infections fall by 84% thanks to vaccination

Cases of rotavirus infections fall by 84% thanks to vaccination

Figures published by Public Health England have shown that the number of diagnosed Rotavirus cases, a highly infectious virus which may cause vomiting and diarrhoea, have dropped by 84% since the introduction of a vaccine to the national childhood immunisation schedule in July 2013. [More]
Crohn's disease sufferers experience slower cognitive response times, study shows

Crohn's disease sufferers experience slower cognitive response times, study shows

New research published in the UEG Journal1 has found that Crohn's disease sufferers experience slower response times than matched individuals that do not have the disease. [More]
Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. [More]
Study finds racial-ethnic disparities in emergency department opioid prescription for pain-related conditions

Study finds racial-ethnic disparities in emergency department opioid prescription for pain-related conditions

Dr. Astha Singhal, Assistant Professor in the Department of Health Policy and Health Services Research at Boston University Henry M. Goldman School of Dental Medicine, published a study that found a racial disparity in opioid prescriptions for emergency department visits for non-definitive pain-related conditions. [More]
Study finds biological basis for gastrointestinal symptoms in people with non-celiac wheat sensitivity

Study finds biological basis for gastrointestinal symptoms in people with non-celiac wheat sensitivity

A new study may explain why people who do not have celiac disease or wheat allergy nevertheless experience a variety of gastrointestinal and extra-intestinal symptoms after ingesting wheat and related cereals. [More]
OMT techniques can help decrease acute pain in postpartum women

OMT techniques can help decrease acute pain in postpartum women

Preliminary results demonstrate that osteopathic manipulative treatment (OMT) helps reduce acute pain in postpartum women, regardless of whether they delivered vaginally or via cesarean. [More]
Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today. [More]
Low-FODMAP rye bread may reduce symptoms of IBS

Low-FODMAP rye bread may reduce symptoms of IBS

Patients with irritable bowel syndrome (IBS) are often concerned that certain foods may trigger or worsen their symptoms, which can include abdominal pain, diarrhea, or constipation. In a new study, patients who ate rye bread that was low in so-called "FODMAPs" (fermentable oligo- di- and mono-saccharides and polyols) experienced milder IBS symptoms than patients who ate normal rye bread. [More]
Researchers play crucial role in crafting diagnostic criteria for functional GI disorders

Researchers play crucial role in crafting diagnostic criteria for functional GI disorders

With no laboratory test available to diagnose functional gastrointestinal disorders, proper diagnostic criteria are critical for clinicians to make an accurate determination of what ails their patients. [More]
FDA approves novel stomach-draining device to treat obesity

FDA approves novel stomach-draining device to treat obesity

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal. [More]
FDA approves Vaxchora for prevention of cholera

FDA approves Vaxchora for prevention of cholera

The U.S. Food and Drug Administration today approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. Vaxchora is the only FDA-approved vaccine for the prevention of cholera. [More]
Metabolite of oral DMF drug for multiple sclerosis appears to slow onset of Parkinson's disease

Metabolite of oral DMF drug for multiple sclerosis appears to slow onset of Parkinson's disease

The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson's disease, researchers say. [More]
Tarantula venom could help provide relief for patients suffering from Irritable Bowel Syndrome

Tarantula venom could help provide relief for patients suffering from Irritable Bowel Syndrome

Researchers from The University of Adelaide in South Australia found that a specific peptide in the spider venom could be used to understand how people sense pain. [More]
Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spiders have helped researchers from Australia and the US discover a new target for irritable bowel syndrome pain. [More]
Duke scientists discover new small-molecule drugs to treat chronic pain

Duke scientists discover new small-molecule drugs to treat chronic pain

A research team at Duke University has discovered a potential new class of small-molecule drugs that simultaneously block two sought-after targets in the treatment of pain. [More]
Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA. [More]
Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

A child feels nauseated all the time, but no medical test can find what is wrong. Or a child vomits regularly, but there's no illness or eating disorder to explain it. These, and other stomach and bowel-related problems with no obvious causes, are called functional gastrointestinal disorders. [More]
ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn. [More]
Advertisement